PONTE
VEDRA, Fla., July 24,
2023 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a
biopharmaceutical company developing tecarfarin, a late-stage novel
oral and reversible anticoagulant (blood thinner) for certain rare
medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and
Compensation and Nomination/Governance Committees. Lisicki brings
over 25 years of experience in the pharma/biotech sector, including
as the Chief Commercial Officer of Arena Pharmaceuticals, where he
provided global visionary leadership for the $6.7 billion growth-stage biopharmaceutical
company through their acquisition by Pfizer in March 2022.
"Robert is a highly accomplished executive with a proven track
record leading rapidly growing clinical-stage public companies,
including successes with cardiovascular therapeutics and strong
relationships with life sciences investors. His experience in
developing collaborative research agreements with large pharma
across multiple therapeutic areas will be a valuable asset as we
look to advance tecarfarin," said Quang
Pham, Chairman and CEO of Cadrenal. "I look forward to
leaning on his executive experience and commercial vision as a
member of the Cadrenal board."
During his time as Chief Commercial Officer at Arena
Pharmaceuticals, Lisicki had a leadership role in more than
$8 billion in M&A activities. He
regularly interacted with FDA, EMA, and PDMA on study and protocol
designs.
Prior to Arena, Lisicki was Vice President, General Manager of
Inflammation & Immunology and Cardiovascular at Regeneron
Pharmaceuticals, where he was responsible for both commercial and
development stage efforts. From 2014 through 2018, Lisicki was
Senior Vice President and Chief Customer Officer of Daichii-Sanyko,
where he managed the successful global product launches in
Cardiovascular and successful U.S. development in Pain and
Oncology. From 2005 through 2014, he held key global roles with
Amgen. Lisicki earned his BS in Finance and Economics from
State University of New York at
Albany.
"I believe Cadrenal Therapeutics is developing a novel and
potentially paradigm-changing therapeutic," said Robert Lisicki. "I look forward to working with
the team to advance the development and value that Tecarfarin may
bring to serious and life-threatening diseases."
Lisicki will occupy a newly created seat on the Cadrenal Board
of Directors.
About Cadrenal Therapeutics, Inc.
Cadrenal
Therapeutics is developing tecarfarin, a late-stage novel oral and
reversible anticoagulant (blood thinner) with orphan drug and Fast
Track designations for the prevention of systemic thromboembolism
(blood clots) of cardiac origin in patients with end-stage kidney
disease, or ESKD, and atrial fibrillation. Tecarfarin is
specifically designed to leverage a different metabolism pathway
than the oldest and most commonly prescribed Vitamin K antagonist
(warfarin) used in the prevention of thrombosis. Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than
1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease
(CKD). For more information, please
visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this
press release about future expectations, plans, and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute "forward-looking statements."
These statements include statements regarding the contributions to
be derived from the appointment of Robert
Lisicki as a member of the board of directors. The
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including the ability to derive the anticipated
benefits from Mr. Lisicki's appointment to the Board of Directors
and the risk factors described in the Company's Annual Report on
Form 10-K for the year ended December 31, 2022, and the
Company's subsequent filings with the SEC, including subsequent
periodic reports on Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. Any forward-looking statements contained in
this press release speak only as of the date hereof and, except as
required by federal securities laws, Cadrenal Therapeutics
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
Contact
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-announces-appointment-of-robert-lisicki-to-board-of-directors-301883700.html
SOURCE Cadrenal Therapeutics, Inc.